Investment Rating - The report recommends focusing on the vocational education company China Oriental Education (00667.HK) due to its strong growth prospects and operational adjustments [12]. Core Insights - The vocational training sector is experiencing an upward trend, driven by an increase in the number of high school graduates who are not entering university, leading to a growing demand for vocational skills training [2][7]. - China Oriental Education has forecasted a significant increase in adjusted net profit for 2025, with a growth rate between 46% and 51%, translating to a profit range of 767 million to 793 million RMB [6][12]. - The company is implementing refined management strategies to enhance operational efficiency, which is expected to result in a gross margin increase of 5.2 percentage points to 56.5% in 2025 [8]. Summary by Sections Market Overview - The education index fell by 3.2% in the week of February 6-12, underperforming the Hang Seng Index by 4.1 percentage points, but has shown a year-to-date increase of 12.86% [5]. Company Updates - China Oriental Education's new training participants are expected to grow by 6% in 2025, contributing to a revenue increase of 12% to 4.61 billion RMB [6][12]. - The company is targeting high school graduates who did not enter university, with a significant increase in the number of such graduates from 119,000 in 2021 to 386,000 in 2024 [7]. Operational Efficiency - The company is focusing on optimizing marketing expenditures and improving school capacity utilization, which is projected to lower the marketing expense ratio by 2.5 percentage points to 21.2% in 2025 [8]. - Management efficiency is also expected to improve, with a projected management expense ratio of 11.2%, down by 1.1 percentage points [8]. Capital Expenditure and Dividends - Capital expenditures are anticipated to decrease by 33.6% to approximately 660 million RMB in 2025, with a high dividend payout ratio expected to yield a dividend yield of 5.6% [9][10]. Investment Recommendations - The report suggests a focus on vocational education companies, particularly China Oriental Education, due to its strong performance forecasts and strategic adjustments to meet the growing demand for vocational training [12].

Core Viewpoint - Boyu Capital has increased its stake in Shanghai Henlius Biotech, Inc. by purchasing 262,500 and 80,000 H-shares, raising its holding from 5.84% to 7% [1][2]. Group 1: Investment Activity - Boyu Capital previously invested HKD 21.27 million to increase its stake from 4.89% to 5.15% on June 18, 2023, crossing the 5% threshold [2]. - The recent purchases reflect Boyu Capital's confidence in the core value and sustainable development potential of Shanghai Henlius in the innovative biopharmaceutical sector [2][3]. Group 2: Product Development and Clinical Progress - Shanghai Henlius has a robust pipeline with key products such as the anti-PD-1 monoclonal antibody Hansizhuang and the PD-L1 ADC HLX43, which have received international recognition for their clinical value [2][3]. - Recent data presented at the "2025 International Lung Cancer Frontier and Innovation Forum" confirmed the efficacy of HLX43 and HLX07, further enhancing market confidence in the company's R&D capabilities [3][5]. Group 3: Commercialization and International Collaboration - The company has established a diverse product matrix and has received global approvals for nine products, with four applications accepted by regulatory agencies in China, the US, and Europe [5]. - Shanghai Henlius has formed commercial partnerships with over 20 international pharmaceutical companies, covering major markets in Europe and the US, which supports its revenue growth [6]. - The company reported a significant increase in overseas product profits, with a 280% year-on-year growth in cash flow from BD contracts, indicating strong future revenue potential [6]. Group 4: Industry Outlook - As the biopharmaceutical industry enters a phase of high-quality development, companies with strong R&D capabilities and mature commercialization systems will become increasingly competitive [8]. - The continuous investment by top-tier capital like Boyu Capital serves as a testament to the intrinsic value demonstrated by Shanghai Henlius through solid clinical data [8].